BioPharmSignal logoBioPharmSignal

Biotech News

MediciNova CEO Provides Shareholder Update

MediciNova (MNOV)MediciNovaCompany update

LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides shareholders an update on key findings from the

Related news

MNOVMediciNova2026-10-06 10:00 EST

MediciNova to Participate in the Maxim Growth Summit

MNOVMediciNova2026-09-28 10:00 EST

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

View all latest news

MediciNova

MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.

Recent company news

MNOVMediciNova2026-10-12 10:00 EST

MediciNova CEO Provides Shareholder Update

MNOVMediciNova2026-10-06 10:00 EST

MediciNova to Participate in the Maxim Growth Summit

MNOVMediciNova2026-09-28 10:00 EST

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-09-24 10:00 EST

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

Stock data

Close
1.45 USD
Market cap
65.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States